Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07618845
Starting soon Phase 1

A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults

NCT07618845 · tracked via the Priya Life Science South Korea tracker
Sponsor
Addpharma Inc
Phase
Phase 1
Started
2026-05
Last updated
2026-06-01

Condition(s) studied

Chronic Liver Disease (CLD)

Investigational drug(s) / intervention(s)

AD-230 (Fasted)AD-230 (Fed)

AD-230 (Fasted): AD-230 1Tab., Per Oral, Fasted

AD-230 (Fed): AD-230 1 Tab., Per Oral, Fed state

Study summary

A clinical trial to assess the pharmacokinetics, safety, and food effect of AD-230 in healthy adults

Eligibility

Sex
ALL
Min age
19 Years
Max age
64 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit * Subjects aged 19 years or older and under 65 years at the screening visit Exclusion Criteria: * Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied

Primary outcome measure(s)

  • Area under the plasma concentration-time curve during dosing interval (AUCt) — -24hours to 72hours
  • Maximum concentration of drug in plasma (Cmax) — -24hours to 72hours

Trial sites (1)

FacilityCityRegionStatus
Kyungpook National university hospital Daegu South Korea

More Addpharma Inc. trials in South Korea

A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects Starting soon
Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 Starting soon
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C Starting soon
A Clinical Trial to Evaluate the Bioequivalence of AD-116A and AD-1161 Under Fed Conditions in Healthy Adult Male Volunteers Starting soon
A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C Starting soon

Other trials for the same condition

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07618845 on ClinicalTrials.gov ↗ ← All trials in South Korea